Is your lot release testing strategy ready for global commercialization?
CHO cells continue to serve as a key cell substrate for the manufacturing of recombinant proteins that span beyond therapeutic monoclonal antibodies and include subunit vaccines.
In this webinar, you will learn:
- CMC testing requirements with CHO production platform for global commercialization
- Lot release testing of product intermediates and the final product
- Product-specific qualification study
- Alternative rapid testing methods to advance lot release testing
Speaker
Edmund Ang, Ph.D.
MilliporeSigma
Senior Technical Specialist
Edmund Ang is a senior technical specialist who provides technical support to biopharma developers and manufacturers in Asia Pacific. He has extensive life science R&D experience in cancer drug and biomarker discovery at Eli Lily and Ionis Pharmaceuticals, as well as commercial experience in cellular analysis and bioproduction with Roche Diagnostics, Life Technologies, and Thermo Fisher Scientific. He holds a Ph.D. in cell biology from the University of Edinburgh and conducted his postdoctoral research on cell signaling at Stanford University and National Cancer Centre, Singapore.
Pharma and biopharma manufacturing
- Cell Line Development
Duration:1hr
Language:English
Session 1:presented May 18, 2021
To continue reading please sign in or create an account.
Don't Have An Account?